Seikagaku (SKUN.F) Stock Overview

Manufactures and sells pharmaceuticals and medical devices primarily related to glycoconjugates in Japan and internationally. More details

SKUN.F fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	3/6
Financial Health	4/6
Dividends	2/6

Rewards

Earnings grew by 21.3% over the past year

Risk Analysis

Earnings have declined by 45.5% per year over past 5 years

Dividend of 4.13% is not well covered by earnings or free cash flows

Shares are highly illiquid

Large one-off items impacting financial results

SKUN.F Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Seikagaku Corporation Competitors

Price History & Performance

Summary of share price highs, lows and changes for Seikagaku
Historical stock prices
Current Share Price	JP¥4.40
52 Week High	JP¥4.68
52 Week Low	JP¥4.40
Beta	0.22
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-71.15%

Recent updates

Shareholder Returns

	SKUN.F	US Pharmaceuticals	US Market
7D	0%	-3.8%	1.4%
1Y	n/a	37.7%	25.7%

Return vs Industry: Insufficient data to determine how SKUN.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how SKUN.F performed against the US Market.

Price Volatility

Is SKUN.F's price volatile compared to industry and market?
SKUN.F volatility
SKUN.F Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	10.4%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.1%

Stable Share Price: SKUN.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine SKUN.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1947	1,144	Ken Mizutani	www.seikagaku.co.jp

Seikagaku Corporation manufactures and sells pharmaceuticals and medical devices primarily related to glycoconjugates in Japan and internationally. It operates in two segments, Pharmaceuticals and LAL Business. The company offers pharmaceuticals and medical devices, including intra-articular injections for improving joint functions under the brands of ARTZ, ARTZ Dispo, VISCO-3, JOYCLU Gel-One, Hylink, and SUPARTZ FX; ophthalmic surgical aids under the OPEGAN and SHELLGAN brands; surgical aids for endoscopic mucosal resection under the brand name of MucoUp; and HERNICORE for the treatment of lumbar disc herniation.

Seikagaku Corporation Fundamentals Summary

How do Seikagaku's earnings and revenue compare to its market cap?
SKUN.F fundamental statistics
Market cap	US$245.78m
Earnings (TTM)	US$9.13m
Revenue (TTM)	US$227.20m

26.9x

P/E Ratio

1.1x

P/S Ratio

Is SKUN.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SKUN.F income statement (TTM)
Revenue	JP¥36.65b
Cost of Revenue	JP¥20.67b
Gross Profit	JP¥15.97b
Other Expenses	JP¥14.50b
Earnings	JP¥1.47b

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

Aug 05, 2026

Earnings per share (EPS)	26.98
Gross Margin	43.59%
Net Profit Margin	4.02%
Debt/Equity Ratio	0.4%

How did SKUN.F perform over the long term?

See historical performance and comparison

Dividends

4.1%

Current Dividend Yield

111%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/21 02:22
End of Day Share Price	2026/04/29 00:00
Earnings	2026/03/31
Annual Earnings	2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Seikagaku Corporation is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Akitada Iwasa	Daiwa Securities Co. Ltd.
Masao Yoshida	Ichiyoshi Research Institute Inc.
Ippei Koga	Marusan Securities Co. Ltd.

Seikagaku CorporationOTCPK:SKUN.F Stock Report